title: Effectiveness and tissue compatibility of a 12-week treatment of chronic venous leg ulcers with an octenidine based antiseptic--a randomized, double-blind controlled study.
abstract: The aim of this study was to evaluate the cytotoxic effect of octenidine dihydrochloride/phenoxyethanol (OHP) found in vitro by conducting a randomized, double-blind controlled clinical study focusing on its safe and effective use in chronic venous leg ulcers. In total, 126 male and female patients were treated with either OHP (n = 60) or Ringer solution (n = 66). The treatment lasted over a period of maximum 12 weeks. For the assessment of the wound-healing process, clinical outcome parameters were employed, that is, time span until 100% epithelization, wound status and the wound surface area were analysed. Side effects were recorded during the study period. The median time to complete ulcer healing was comparable between the OHP and Ringer solution groups (92 versus 87 days; P = 0·952), without being influenced by wound size or duration of the target ulcer (P-values: 0·947/0·978). In patients treated with OHP, fewer adverse events (AEs) were observed compared with the Ringer group (17% versus 29% of patients reported 20 versus 38 AEs). OHP is well suitable for the treatment of chronic wounds without cytotoxic effects. Furthermore, OHP does not impair the wound healing in chronic venous ulcers.
authors.affiliation: wolfgangvanscheidt@t-online.de
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Vanscheidt
authors.forename: Keith
authors.initials: K
authors.lastname: Harding
authors.forename: Luc
authors.initials: L
authors.lastname: Téot
authors.forename: Jörg
authors.initials: J
authors.lastname: Siebert
mesh_terms: D000368:Aged; D000891:Anti-Infective Agents, Local / Q000008:administration & dosage / Q000627:therapeutic use*; D002908:Chronic Disease; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006648:Histocompatibility; D006801:Humans; D007097:Imines; D008297:Male; D009779:Occlusive Dressings; D011725:Pyridines / Q000008:administration & dosage / Q000627:therapeutic use*; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome; D014647:Varicose Ulcer / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D014945:Wound Healing / Q000187:drug effects / Q000276:immunology*
chemical_list: D000891:Anti-Infective Agents, Local; D007097:Imines; D011725:Pyridines; C034213:octenidine
references.citation: Skin Pharmacol Physiol. 2010;23(5):244-58
references.pmid: 20484966
references.citation: Acta Dermatovenerol Alp Pannonica Adriat. 2004 Dec;13(4):119-23
references.pmid: 15818446
references.citation: Wound Repair Regen. 2003 Mar;11 Suppl 1:S1-28
references.pmid: 12654015
references.citation: Br J Nurs. 2010 Jun 10-23;19(11):S12, S14-6
references.pmid: 20622785
references.citation: Case Manager. 2005 Mar-Apr;16(2):62-3, 67
references.pmid: 15818347
references.citation: Skin Pharmacol Physiol. 2004 May-Jun;17(3):141-6
references.pmid: 15087593
references.citation: Transfus Apher Sci. 2004 Apr;30(2):145-51
references.pmid: 15062754
references.citation: Int Wound J. 2010 Feb;7(1):62-9
references.pmid: 20409252
references.citation: Ostomy Wound Manage. 2005 Jan;51(1):28-34
references.pmid: 15695833